16 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Takeda's employees are committed
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
kyac0h
PFE
TAK
1 Jun 24
a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
7q1kb29xtot73bf 7ze5dkuct8uawavwkyt4ri4k8qncadtmjhros
TAK
31 May 24
, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values
ilrxujrkzyl4edo58yeqsor12t6flayz1e6a1zosk nrr7menu
TAK
16 May 24
collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life
x3s5f
ACIU
TAK
13 May 24
of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered
7cxd08vovihpk4m xod6
ACIU
TAK
13 May 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
jrcd0gw8id3aayedss1oub0w4dr8x4uv3p9 ceyh0mbrv88m6w03anucb
TAK
9 May 24
, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading
hkrnpp1ppz1x12zgyeysuekpok
TAK
26 Apr 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
1y2oxxhy84jqtrhjgf2wc9x5cuaimls5po4ghxcwor
TAK
22 Apr 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven
yzjdmrp0ljt asy8b3amr3m9etvhgaxgmsxa0xogkjlmpbaxry3huaslmwq
TAK
18 Apr 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
hauy58jxa8 fra4kts7n6a9
TAK
27 Mar 24
options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality- diverse pipeline. Our employees
g0ebv9j 4d113pvq7
TAK
26 Mar 24
partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading
- Prev
- 1
- Next